Introduction {#S1}
============

The human leukocyte antigen (HLA) genes are the most polymorphic coding loci known in humans. The HLA gene cluster is located on the major histocompatibility complex (MHC) on chromosome 6, and contains over 200 genes. The two groups of loci that contain the MHC class I and II genes dictating T cell responses are the most polymorphic. It is widely accepted that this variability is maintained by balancing selection, as individuals that are heterozygous in their HLA class I and II loci seem to have a better outcome in infections diseases \[see e.g., for HIV-1 ([@B1])\]. In line with this, it has been demonstrated that in several species, and up to a certain extent in humans, females prefer to mate with males having a dissimilar HLA to increase the chance of their offspring to survive infectious diseases ([@B2], [@B3]). We have argued that the heterozygous advantage is on its own not enough to maintain such a large degree of polymorphism, and that the frequency dependent co-evolution with pathogens should also play a major role ([@B4]).

On the functional level the HLA polymorphism seems to be much smaller. It is well established that MHC class II molecules have largely overlapping peptide repertoires \[see e.g., ([@B5])\]. In the last few years we and others showed this to be also true for class I alleles ([@B6]--[@B9]). This promiscuous peptide binding is not limited to the alleles within each locus, and extends to alleles from different MHC class I loci ([@B7], [@B9]). This property has important evolutionary consequences as heterozygous individuals carrying genetically different HLA molecules that nevertheless have overlapping peptide repertoires should have a diminished heterozygous advantage.

Recombinations occur frequently in the HLA region and they generate novel HLA haplotypes ([@B10]). However, the number of haplotypes found in human populations is far lower than the number of alleles observed ([@B11]), suggesting that not all the HLA haplotypes have the same chance of becoming established in human populations. Indeed, different haplotypes occur with very different frequencies in different ethnic groups/subpopulations[^1^](#fn1){ref-type="fn"} ^,^[^2^](#fn2){ref-type="fn"}. The "usefulness" of HLA molecules is expected to play a role in determining the haplotype frequencies: haplotypes carrying HLA molecules that are protective for certain diseases are expected to be present in relatively high frequencies in endemic areas. Indeed, several HLA haplotype disease associations have been established, e.g., in autoimmune diseases ([@B12]), squamous cell cervical cancer ([@B13]) and recurrent aphthous stomatitis ([@B14]). Along these lines, one can speculate that it should be advantageous to have MHC molecules with distinct binding specificities in a haplotype, because such haplotypes would provide an individual with more epitopes eliciting T cell responses during an infectious disease than haplotypes containing HLA molecules with similar binding motifs. This hypothesis is rather impossible to test experimentally, because one needs to determine the total set of peptides presented by a very large set of HLA molecules in cells infected by different viruses. Such experiments (e.g., eluting peptides from HLA molecules expressed by a cell) are typically done at small scales because they are time consuming. Therefore, we here study the peptide repertoires of HLA molecules that are estimated to be combined in a haplotype (i.e., the ones with a strong linkage disequilibrium) using an *in silico* approach. This approach unfortunately suffers of two main limitations. First, the quality of the peptide-HLA predictions differs between the loci. The quality of HLA-A and HLA-B peptide binding predictions is very reliable. For the other loci (HLA-C, HLA-DR, etc.) the predictions are of low quality ([@B15]), and are therefore left out of this analysis. Second, having distinct HLA binding motifs might also be important in the context of cancer or autoimmunity, however, it is very complicated to determine the role of HLA haplotypes in these diseases. Therefore, we perform our analysis explicitly for infectious diseases, and focus on the peptides that can be presented from common viruses only. Still, we think that our study is a first step to investigate the role of HLA binding motifs in the evolution of HLA haplotype frequencies.

Materials and Methods {#S2}
=====================

NMDP data {#S2-1}
---------

All estimated HLA-A-B haplotype frequencies were downloaded from the National Marrow Donor Program (NMDP) database, which was established to develop and maintain a registry of HLA-typed volunteer unrelated donors for patients requiring a hematopoietic stem cell transplant ([@B16])[^3^](#fn3){ref-type="fn"}. Four predominant US ethnic and racial groups were included in this data set: European Americans, African Americans, Asians, and Hispanic ([@B17]). Haplotype frequencies were estimated separately for each ethnic group using an implementation of the expectation maximization (EM) algorithm ([@B18], [@B19]).

The linkage disequilibrium, *D*, between two alleles in each haplotype was expressed as the difference between the observed and expected haplotype frequency: *D* = *f~AB~*~−~*f~A~f~B~*, where *f~AB~* is the observed (estimated) haplotype frequency, *f~A~* is the allele frequency of the HLA-A molecule in the haplotype and *f~B~* is the allele frequency of the HLA-B molecule in this haplotype. *D* is easy to calculate, but has the disadvantage of depending on the frequency of the alleles. In order to overcome this drawback, the normalized measure, D′, was calculated a $D\prime = \frac{D}{D_{\max}},$ where *D*~max~ is the lesser of *f~AB~* or (1 − *f~A~*) (1 − *f~B~*) when *D* \< 0 and is the lesser of *f~A~*(1 − *f~B~*) or *f~B~*(1 − *f~A~*) when *D* \> 0. The advantage of this measure of disequilibrium is that it ranges between −1 and 1, regardless of the allelic frequencies in the sample. $\left| {D\prime} \right| = 1$ indicates complete LD and *D*′ = 0 corresponds to total absence of LD.

Linkage disequilibrium statistics were calculated for each haplotype to identify the haplotypes that have a significantly positive *D*′.

HLA ligand prediction {#S2-2}
---------------------

To be able to perform our analysis for as many as possible HLA molecules, we used NetMHCpan ([@B15]) to predict peptide-HLA binding affinity. NetMHCpan assigns to each peptide-HLA pair a predicted IC50 value, indicative of the predicted binding affinity. To assess whether a peptide binds to an HLA molecule depends on the choice of binding threshold, and the optimal threshold has been discussed ([@B20]). If one assumes that all HLA molecules use a fixed threshold, one can use the default threshold of 500 nM ([@B21], [@B22]), otherwise a 5000 nM threshold can be used to allow for the comparison of more weakly binding peptides. However, using a fixed threshold to define predicted binders result in large differences in the predicted repertoire sizes between HLA molecules. For instance using a fixed threshold of 500 nM, the HLA repertoire sizes range between 20 and 6574 peptides for the viral set listed in Table S2 in Supplementary Material. As such a variance could introduce large biases in our analysis, we defined the 1% top-ranking peptides as candidate binders for each HLA molecule. This gives each HLA molecule the same ligand repertoire size (i.e., 570 binders per HLA molecule for the viral set listed in Table S2 in Supplementary Material). To check the consistency of our results with respect to these parameters, we repeated every analysis with the fixed threshold of 500 nM. All results presented below were derived using the threshold of 1% to define candidate binders, and remain similar for a fixed threshold, unless mentioned otherwise. To test whether our results change if one were to use a much larger data set, we also generated predicted binders using a much larger set of viruses (see below), in which case each HLA molecule had 60-fold more binders.

Viral data {#S2-3}
----------

The proteomes of 17 common human viruses were downloaded from the European Bioinformatics Institute website[^4^](#fn4){ref-type="fn"} (downloads were made in October 2006, listed in Table S2 in Supplementary Material) as the source of potential HLA ligands. To extend this data set, we downloaded another set of proteomes (downloads were made in October 2008)^4^ from viruses that are known to infect mammalians (*n* = 904). We used the HLA-peptide binding predictors (see above) to screen all possible unique virus-derived 9-mer peptides.

Peptide repertoire overlap {#S2-4}
--------------------------

We define the peptide repertoire overlap between two HLA alleles in the same HLA-A-B haplotype, *F~p~*, as the fraction of overlapping ligands between these two HLA class I molecules among all of their ligands: $F_{p} = \frac{A\bigcap B}{A\bigcup B}$, where *A* and *B* are the ligand sets for HLA-A and -B molecule, respectively. *F~p~* = 1 implies that the HLA-A and HLA-B molecules belonging to the same haplotype have the same epitope repertories while *F~p~* = 0 indicates completely different peptide repertoires for two HLA molecules.

Results and Discussion {#S3}
======================

Determining HLA-A-B haplotypes {#S3-5}
------------------------------

The "true" HLA haplotypes can be determined either by molecular haplotyping or family-based segregation studies ([@B23]--[@B25]). However, both approaches are expensive and laborious, and therefore, statistical methods are typically used to infer haplotypes from datasets covering large population of individuals with known HLA genotypes ([@B26]). Several methods have been proposed to infer HLA haplotypes from genotype data, and in recent studies the performance of two most commonly used approaches, EM algorithm based (implemented in Arlequin V3.0), and the Bayesian algorithm based (implemented in PHASE V2.1.1), have been compared ([@B27], [@B28]). Unfortunately, neither of the methods could infer all of the known haplotypes: incorrect haplotypes were estimated in more than 30% of the cases. However, once the sample size increases, the power of these statistical methods is expected to increase tremendously.

National marrow donor program^2^ provides, to our knowledge, the largest repository of HLA-typed donors. Here use of statistical methods should become more reliable ([@B16]): for the HLA-A-B haplotype, the total chromosome counts (2N) for the four major ethnic groups exceeds 2000. On the NMDP webpage^3^, the high-resolution allele and haplotype frequencies \[estimated by EM method, ([@B18], [@B19])\] are available ([@B17]). Focusing on HLA-A-B haplotypes, the most common haplotypes found in US population (separated into four main ethnic groups) are summarized in Table [1](#T1){ref-type="table"} (adopted from [bioinformatics.nmdp.org](bioinformatics.nmdp.org), December 2007 version). Alternatively Allele frequencies web server^1^, provides allele frequencies established in smaller, but probably better defined studies ([@B29]).

###### 

**Occurrences of the three most common HLA-A-B frequency ranked haplotypes in four major ethnic groups in US (adopted from [bioinformatics.nmdp.org](bioinformatics.nmdp.org))**.

                EUR    AFA   API    HIS                       
  ------ ------ ------ ----- ------ ----- ------ ----- ------ -----
  0101   0801   9.55   1     1.50   6     0.41   46    2.21   2
  0201   4402   5.70   3     1.33   9     0.17   130   1.94   4
  0201   4501   0.05   200   1.66   3     --     --    0.23   105
  0201   5101   2.00   9     0.61   26    0.91   25    2.20   3
  0207   4601   --     --    --     --    3.34   2     --     --
  0301   0702   6.01   2     1.73   2     0.26   82    1.92   5
  2902   4403   2.38   7     1.08   15    0.03   433   2.54   1
  3001   4201   --     --    2.96   1     --     --    0.40   50
  3303   4403   --     --    0.09   261   2.94   3     0.16   156
  3303   5801   0.08   162   0.28   88    4.53   1     0.10   230

EUR, Caucasian; AFA, African; API, Asian; HIS, Hispanic. *F* stands for population frequency in percentages.

In the NMDP database 660 possible haplotypes are reported for European Americans. However, many of these haplotypes are bound to be falsely predicted, e.g., due to the limited number of individuals carrying particular combinations of specific HLA molecules. To decrease the amount of wrongly identified haplotypes in our analysis, we apply a rather strict criterion for considering a predicted haplotype as a "true" haplotype: we demand a positive LD value that is significantly different than zero (*p* \< 0.01, see [Materials and Methods](#S2){ref-type="sec"}). This criterion decreases the number of haplotypes to 60 for European Americans. These 60 haplotypes are estimated to cover 58% of the population (see Table [2](#T2){ref-type="table"}), i.e., current statistical methods and data sets (even the large repositories like NMDP) remain rather limited in providing the HLA haplotype diversity of a population. For other ethnical groups, the number of reliable haplotypes drops to 30--40 per ethnic group, even though the number of possible haplotypes was the same or higher (see Table [2](#T2){ref-type="table"} and footnote text 3). The population coverage in non-European groups was lower, 30--40% of their respective populations, possibly due to the lower number of individuals with known HLA-typing. All together we detected 120 reliable unique haplotypes by summing over these ethnical groups (the full list of haplotypes can be found in Table S1 in Supplementary Material).

###### 

**Numbers of different haplotypes with a significantly positive LD in four major US ethnic groups**.

  Ethnicity   Haplotype \# (%)
  ----------- ------------------
  EUR         60 (57.7)
  API         34 (35.4)
  HIS         43 (33.5)
  AFA         43 (33.7)

Population coverage in percentages is given within parenthesis.

Peptide repertoire of an haplotype {#S3-6}
----------------------------------

Having identified the HLA-A-B haplotypes for the US population, we next estimated the overlaps between peptide repertoires of HLA-A and -B molecules that belong to the same haplotype.

We used an *in silico* approach and predicted the peptide repertoire of all HLA-A and HLA-B alleles that are part of the 120 predicted haplotypes, using the proteomes of common viruses (see Table S2 in Supplementary Material) and HLA-peptide binding predictor NetMHCpan ([@B15], [@B30]) (see [Materials and Methods](#S2){ref-type="sec"}). NetMHCpan is the only prediction system available right now that can reliably predict the peptide binding affinities for the large set of HLA-A and HLA-B molecules we are taking into account in this study. The analysis of the 120 significant haplotypes demands predictions for 39 HLA-A and 63 HLA-B molecules. This predictor assigns an IC50 value to each peptide-HLA pair, which can be used as a predicted binding affinity. Using the widely accepted IC50 value of 500 nM as a threshold to distinguish binders from non-binders, generated a large variation in the predicted repertoire sizes of different HLA molecules (20--6574 peptides for the viral set listed in Table S2 in Supplementary Material), which could strongly bias our results. As the physiologically relevant IC50 values are difficult to estimate for each HLA molecule, we have chosen a simplified approach and define the peptide repertoire as the top 1% peptides with the highest HLA binding affinities for each HLA molecule. This approach removes the potential bias introduced by different repertoire sizes, but ignores the fact that some HLA molecules can be more specific than others, and therefore present much fewer peptides.

The unique haplotypes listed in Table S1 in Supplementary Material have an average peptide overlap of 1.1% (with a standard deviation of 1.8%, and a median of 0.44%) using top 1% threshold. The distribution of the overlaps is given in Figure [1](#F1){ref-type="fig"}A, and varies somewhat among the haplotypes. Out of 120 haplotypes, 36 (30%) have non-overlapping peptide repertoires, at least for the common viruses that we tested (see Table S1 in Supplementary Material). Only for five haplotypes is the repertoire overlap higher than 5%, and HLA-A0101-B1517 with an overlap of 11.8% is the highest. HLA-A0101-B1517 is a rare haplotype and occurs only in Asian Americans with a population frequency of 0.4%. To test whether or not rare haplotypes tend to have larger overlaps than common haplotypes, we weighted the overlaps found in Figure [1](#F1){ref-type="fig"}A with the population frequency of the HLA-A-B haplotypes (Figure [1](#F1){ref-type="fig"}B). Since the weighted overlaps remain very similar to the unweighted overlaps (Figures [1](#F1){ref-type="fig"}A,B), there is no evidence for a trend of rare haplotypes having the largest overlaps. In line with this, the frequency of a haplotype is only weakly correlated with the degree of peptide overlap between the haplotype's HLA-A and HLA-B molecules (*r* = −0.08, *p* = 0.4, Spearman rank correlation). Apparently, there is no selection pressure increasing the frequency of the haplotypes with a small peptide repertoire overlap.

![**Distribution of the presented peptide overlap (given in percentages, see [Materials and Methods](#S2){ref-type="sec"}) between HLA-A and HLA-B molecules belonging to the same haplotype**. **(A)** The distribution of the peptide overlaps for the 120 unique haplotypes we identified in the US population. **(B)** The distribution in A is weighted with the frequency of the haplotype in the population. If a haplotype was found in more than one ethnicity in US, we have taken the maximum frequency into account, normalizing the frequencies such that the sum remains one. In **(C)** we plot the overlaps found in artificially generated haplotypes (created by reshuffling the HLA-A and -B molecules from the 120 unique haplotypes). This plot is representative of 100 sets of artificially generated haplotypes. **(D)** The weighted peptide overlaps for the artificial haplotypes, where we estimate the frequency of the haplotype as the multiplication of the frequency of HLA-A and HLA-B molecule in the population (normalized to let the sum of the frequencies of the artificial haplotypes remain one).](fimmu-04-00374-g001){#F1}

These results were obtained using the top 1% peptides with the highest HLA binding affinities as the set of presented peptides per molecule. Using the set of common viruses listed in Table S2 in Supplementary Material, this threshold results in approximately 570 predicted binders per HLA molecule. To test whether the results presented in Figure [1](#F1){ref-type="fig"}A would be sensitive to the number of peptides, we collected proteomes for a much larger set of mammalian viruses (*n* = 904), which contains approximately three million unique peptides of nine amino acids. Using the same 1% threshold for this larger set, we predict for each HLA molecule the extended peptide repertoire and calculate the overlaps as explained before. The distribution of the overlaps hardly changes despite the fact that we enlarged the presented peptide repertoire 60-fold per molecule (see Figure S1 in Supplementary Material). As the results presented in Figure [1](#F1){ref-type="fig"}A seem fairly insensitive to the number of peptides used, we perform the rest of the analysis on the small data set of common viruses.

To test whether or not HLA binding motifs affect haplotype compositions requires comparison of the peptide overlaps of "true" haplotypes with those of "random" haplotypes. To do this, we reshuffled HLA-A and HLA-B molecules in the 120 "true" haplotypes to calculate an expected peptide repertoire overlap for randomly made haplotypes. Although the HLA molecules in random haplotypes can have overlaps up to 28% in their peptide repertoires (see Figure [1](#F1){ref-type="fig"}C and results not shown), the distribution of the overlaps is not significantly different from the distribution given in Figure [1](#F1){ref-type="fig"}A. The set of random haplotypes was generated 100 times, and in none of these cases was the distribution significantly different from the one given in Figure [1](#F1){ref-type="fig"}A (using a Kolmogorov--Smirnov test). Finally, we calculated a weighted peptide repertoire overlap for the random haplotypes by assuming that the frequency of a random haplotype is simply the multiplication of the frequency of their HLA-A and HLA-B alleles (i.e., assuming a complete lack of linkage disequilibrium). Again, the distribution of weighted overlap of random haplotypes (Figure [1](#F1){ref-type="fig"}D) is not different from that of the real haplotypes (Figure [1](#F1){ref-type="fig"}B). Taken together, these results suggest that HLA-A and -B in pairs in general have distinct peptide binding preferences, and that a small overlap is not a unique property of the HLA molecules having a strong linkage disequilibrium.

The overlap distribution presented in Figure [1](#F1){ref-type="fig"} seems to be in contradiction with earlier results, which estimated cross loci peptide overlaps of 23--44% ([@B7], [@B9]). However, this overlap was estimated at the population level, i.e., these percentages reflect the fraction of the peptide repertoire of an HLA-A molecule which is also expected to be presented by at least one HLA-B molecule in the population (and vice versa). Within an individual having maximally two different HLA-A and HLA-B molecules, the overlaps should remain much lower than the population based overlaps. In addition, one needs to realize that the low overlaps presented in Figure [1](#F1){ref-type="fig"} depend on the threshold used to define the peptide repertoire of an HLA molecule. When we use a higher threshold of 2 or 5% the average overlap increases to 2.3 and 5.9%, respectively (with the standard threshold of 1%, the average overlap was 1.1%, see above). However, the choice of the threshold hardly affects our main result, namely that the HLA-A and -B pairs that are in a linkage disequilibrium do not have more distinct binding motifs than random HLA-A/B pairs (Figure [1](#F1){ref-type="fig"}).

Conclusion {#S4}
==========

We hypothesized that it should be advantageous to have HLA molecules with distinct binding specificities combined in a haplotype, because during a viral infection such haplotypes would give an individual a larger epitope repertoire than haplotypes containing HLA molecules with similar binding motifs during a viral infection. To test this hypothesis, we used the high-resolution data available in the NMDP database on haplotype frequencies, and employed state of the art peptide-HLA binding prediction tools. We find that for all the haplotypes we could reliably identify in the US population, their HLA-A and HLA-B molecules present largely distinct set of peptides (Figure [1](#F1){ref-type="fig"}A). However, this turned out to be a generic property of HLA-A and HLA-B molecules: when we compared random HLA-A and -B pairs we find a very similar distribution of the presented peptide overlaps (Figure [1](#F1){ref-type="fig"}C). Moreover, there is no evidence for selection as there is no correlation between the population frequency of the HLA-A-B haplotypes and the overlap in the peptide repertoires of their HLA-A and HLA-B molecules. Taken together, these results suggest the complementarity of binding motifs is a general property of HLA-A and HLA-B molecules, and that complementarity does not affect the HLA haplotype composition. We were not able to specifically test the effect of complimentary binding motifs in the context of autoimmunity and cancer, as for both cases it remains unclear which set of human proteins should be taken as possible auto antigens. Complimentary binding motifs are expected to increase the number of potential self antigens, which could increase the risk of autoimmunity. Finally, the frequency of an HLA haplotype is determined by complex interactions with many different factors, one example is the correlation between birth weight and particular haplotypes ([@B31]). Our results suggest that complimentary binding motifs of HLA molecules during viral infections play a minor role, if any, compared to these other factors in the evolution of HLA haplotype frequencies.
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